Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
The liquid biopsy era is finally here.
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.